SecBot SecBot
SECBOTREPLAY Home › Report › GMAB

GMAB · Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207…

GENMAB A/S · 6-K filed Jul 15, 2026 at 07:22 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Jul 15, 2026 at 07:22 ET

Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207 million, with USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. The company receives royalties on these sales from Johnson & Johnson. This is a routine quarterly sales update without comparative data or guidance, providing a top-line indicator of Genmab's primary revenue driver.

  • Worldwide net trade sales of DARZALEX in Q2 2026 totaled USD 4,207 million.
  • U.S. net sales were USD 2,435 million; rest of world net sales were USD 1,772 million.
  • Genmab receives royalties on worldwide DARZALEX sales under its license with Johnson & Johnson (Janssen).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access